Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current treatment of Hodgkin's disease.
Eghbali H, Soubeyran P, Tchen N, de Mascarel I, Soubeyran I, Richaud P. Eghbali H, et al. Among authors: tchen n. Crit Rev Oncol Hematol. 2000 Jul;35(1):49-73. doi: 10.1016/s1040-8428(99)00070-0. Crit Rev Oncol Hematol. 2000. PMID: 10863151 Review.
Follicular lymphomas--a review of treatment modalities.
Soubeyran P, Debled M, Tchen N, Richaud P, Monnereau A, Bonichon F, Eghbali H. Soubeyran P, et al. Among authors: tchen n. Crit Rev Oncol Hematol. 2000 Jul;35(1):13-32. doi: 10.1016/s1040-8428(00)00066-4. Crit Rev Oncol Hematol. 2000. PMID: 10863149 Review.
Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients.
Tchen N, Soubeyran P, Eghbali H, Ceccaldi J, Cany L, Balzon JC, Remuzon P, Malet M, Bonichon F, Picot V, Monnereau A, Hoerni B; Sud-Ouest Lymphomes. Tchen N, et al. Crit Rev Oncol Hematol. 2002 Sep;43(3):219-26. doi: 10.1016/s1040-8428(01)00200-1. Crit Rev Oncol Hematol. 2002. PMID: 12270778
Taxane-induced glaucoma.
Fabre-Guillevin E, Tchen N, Anibali-Charpiat MF, Calluaud L, Ravaud A. Fabre-Guillevin E, et al. Among authors: tchen n. Lancet. 1999 Oct 2;354(9185):1181-2. doi: 10.1016/S0140-6736(99)03019-6. Lancet. 1999. PMID: 10513720
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.
Fiedler W, Tchen N, Bloch J, Fargeot P, Sorio R, Vermorken JB, Collette L, Lacombe D, Twelves C; EORTC new drug development group. Fiedler W, et al. Among authors: tchen n. Eur J Cancer. 2006 Jan;42(2):200-4. doi: 10.1016/j.ejca.2005.07.030. Epub 2005 Dec 7. Eur J Cancer. 2006. PMID: 16337787 Clinical Trial.